Katherine Malone, Associate Director of Research, presents a leaner strategic approach to anti-drug antibody (ADA) assessments to support nonclinical toxicology studies. Nonclinical ADA assessments are rarely predictive, rather they inform on altered PK/PD profiles or immune-mediated reactions. This session describes a fit for purpose approach, which focusses on the necessary integrations with findings from critical toxicology study endpoints and explores a change in paradigm from a lengthy multi-tier assessment approach to a leaner screening-only assay approach.
About the Presenter
Katherine Malone
Associate Director Research Lab Sciences